Days to Clear pfs25 With 2 Doses of Primaquine Administered to Subjects in Cohort 3
| Cohort 3 . | No. . | Primaquine Dose . | Time to Clear, d, Mean (95% CI) . | Slope of Decay Curve (95% CI of Slope) . |
|---|---|---|---|---|
| Group 1 | 4 | 45 mg | 4.5 (2.5–6.6) | 0.921 (.566–1.275) |
| Group 2 | 4 | 15 mg | 12.0 (2.0–22.0) | 0.400 (−.020 to .819) |
| Group 3 | 4 | 0 | >11 | 0.032 (−.008 to .070) |
| Cohort 3 . | No. . | Primaquine Dose . | Time to Clear, d, Mean (95% CI) . | Slope of Decay Curve (95% CI of Slope) . |
|---|---|---|---|---|
| Group 1 | 4 | 45 mg | 4.5 (2.5–6.6) | 0.921 (.566–1.275) |
| Group 2 | 4 | 15 mg | 12.0 (2.0–22.0) | 0.400 (−.020 to .819) |
| Group 3 | 4 | 0 | >11 | 0.032 (−.008 to .070) |
One-way analysis of variance was used estimate mean and 95% confidence intervals (CIs) for days to clearance [14]. The slope of the decay curve was estimated by simple linear regression of the log10pfs25 transcript count against days. All pair-wise differences were significantly different (P < .05).
Days to Clear pfs25 With 2 Doses of Primaquine Administered to Subjects in Cohort 3
| Cohort 3 . | No. . | Primaquine Dose . | Time to Clear, d, Mean (95% CI) . | Slope of Decay Curve (95% CI of Slope) . |
|---|---|---|---|---|
| Group 1 | 4 | 45 mg | 4.5 (2.5–6.6) | 0.921 (.566–1.275) |
| Group 2 | 4 | 15 mg | 12.0 (2.0–22.0) | 0.400 (−.020 to .819) |
| Group 3 | 4 | 0 | >11 | 0.032 (−.008 to .070) |
| Cohort 3 . | No. . | Primaquine Dose . | Time to Clear, d, Mean (95% CI) . | Slope of Decay Curve (95% CI of Slope) . |
|---|---|---|---|---|
| Group 1 | 4 | 45 mg | 4.5 (2.5–6.6) | 0.921 (.566–1.275) |
| Group 2 | 4 | 15 mg | 12.0 (2.0–22.0) | 0.400 (−.020 to .819) |
| Group 3 | 4 | 0 | >11 | 0.032 (−.008 to .070) |
One-way analysis of variance was used estimate mean and 95% confidence intervals (CIs) for days to clearance [14]. The slope of the decay curve was estimated by simple linear regression of the log10pfs25 transcript count against days. All pair-wise differences were significantly different (P < .05).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
